Article

Drug combination shows significant survival advantage in metastatic RCC

The combination of bevacizumab (Avastin) and interferon-alpha (Roferon-A) as first-line treatment in patients with metastatic renal cell carcinoma offers significant improvement in progression-free survival compared with interferon-alpha alone, according to a study published in The Lancet (2007; 370:2103-11).

Related Videos
2 experts in this video
2 experts in this video
Related Content
© 2025 MJH Life Sciences

All rights reserved.